These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 1543949

  • 1. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
    Ratanatharathorn V, Karanes C, Lum LG, Uberti J, Dan ME, de Planque MM, Schultz KR, Cronin S, Leisz MC, Mohamed A.
    Bone Marrow Transplant; 1992 Jan; 9(1):49-55. PubMed ID: 1543949
    [Abstract] [Full Text] [Related]

  • 2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 3. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR, Berger C, Kröger N, Stockshläder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schönrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Witt M, Hossfeld KD, Weh HJ.
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [Abstract] [Full Text] [Related]

  • 4. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 5. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K.
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB, Myers S, Devine S, Larson RA, Williams SF, Park CL, O'Toole K, Chandler C, Topper RL.
    Bone Marrow Transplant; 1992 Jan; 9(1):41-7. PubMed ID: 1543948
    [Abstract] [Full Text] [Related]

  • 7. Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia.
    Crilley P, Topolsky D, Bulova S, Bigler R, Brodsky I.
    Bone Marrow Transplant; 1990 Mar; 5(3):187-91. PubMed ID: 2331539
    [Abstract] [Full Text] [Related]

  • 8. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG, Warkentin PI, Strandjord SE, Abromowitch M, Bayever E, Harper JL, Coccia PF.
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 11. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
    Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D.
    Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T, Kojima S, Kato K.
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, Holmes W, Becker P, Roberts KB, Rappeport JM.
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [Abstract] [Full Text] [Related]

  • 14. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG.
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [Abstract] [Full Text] [Related]

  • 15. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C, Braine HG, Kaizer H, Saral R, Tutschka PJ, Santos GW.
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [Abstract] [Full Text] [Related]

  • 16. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, Andresen S, Kuczkowski E, Bolwell B.
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [Abstract] [Full Text] [Related]

  • 17. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
    Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, Deeg HJ.
    Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I, Klein JL, Kapoor N, Harman GS, Avalos BR.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [Abstract] [Full Text] [Related]

  • 19. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N.
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [Abstract] [Full Text] [Related]

  • 20. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ.
    Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.